Related Experiment Video

Updated: Jun 19, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Clinical experience in the treatment of lower respiratory tract infections with ceftazidime

T Pettersson1, P Ahvonen, E Storgårds

  • 1Department of Medicine, Aurora Hospital, Helsinki, Finland.

The Journal of Antimicrobial Chemotherapy
|October 7, 2009
PubMed

Insights

Ceftazidime effectively treated lower respiratory tract infections in 15 elderly patients with underlying conditions. Most patients experienced positive outcomes, with eleven cured and one improved, demonstrating ceftazidime

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Internal Medicine

Background:

  • Lower respiratory tract infections (LRTIs) pose significant health challenges, particularly in elderly populations with comorbidities.
  • Effective antibiotic therapy is crucial for managing LRTIs and preventing complications.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of ceftazidime in treating lower respiratory tract infections.
  • To assess treatment outcomes in a cohort of elderly patients with underlying health conditions.

Main Methods:

  • A clinical study involving 15 patients diagnosed with lower respiratory tract infections.
  • Treatment administered with ceftazidime.
  • Patient outcomes, including clinical cure, improvement, and adverse events, were monitored.

Main Results:

  • Ceftazidime demonstrated high efficacy, with 11 out of 15 patients cured and one showing improvement.
  • Bacteriological failure was observed in one case.
  • Adverse events were infrequent, including local pain (2 cases), skin rash (1 case), and transient elevated liver enzymes (1 case).

Conclusions:

  • Ceftazidime is an effective treatment option for lower respiratory tract infections in elderly patients with comorbidities.
  • The antibiotic was generally well-tolerated, with a low incidence of side effects.
  • Further research may explore ceftazidime's role in specific subpopulations with LRTIs.

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Related Concept Videos

Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Urinary Tract Infection I: Introduction01:26

Urinary Tract Infection I: Introduction

Urinary tract infections (UTIs) impact various parts of the urinary system, including the kidneys, ureters, bladder, and urethra. These infections are generally bacterial, with Escherichia coli being the most common causative agent, often originating from the gastrointestinal tract. However, other bacteria, such as Staphylococcus saprophyticus, Klebsiella pneumoniae, and Proteus mirabilis, are also known to cause UTIs. The type, location, and underlying complexity of the UTI guide both...